NCT02108600View on ClinicalTrials.gov

Tocilizumab for Renal Graft Inflammation

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

December 16, 2018

Study Completion Date

December 16, 2018

Conditions
Late Complication From Kidney Transplant
Interventions
DRUG

Tocilizumab

Will receive tocilizumab 8 mg/kg intravenously at four-week intervals for a total of 6 doses. In addition, will continue usual immunosuppressive regimen.

Trial Locations (1)

94143

University of California, San Francisco, San Francisco

All Listed Sponsors
lead

Flavio Vincenti

OTHER

NCT02108600 - Tocilizumab for Renal Graft Inflammation | Biotech Hunter | Biotech Hunter